View Future GrowthAccent Microcell 過去の業績過去 基準チェック /46Accent Microcellは、平均年間29%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間14.2% 15.1%収益成長率で 成長しています。 Accent Microcellの自己資本利益率は15.9%であり、純利益率は12.6%です。主要情報29.03%収益成長率21.50%EPS成長率Pharmaceuticals 業界の成長17.49%収益成長率15.12%株主資本利益率15.92%ネット・マージン12.57%前回の決算情報31 Mar 2026最近の業績更新分析記事 • May 20Accent Microcell's (NSE:ACCENTMIC) Profits Appear To Have Quality IssuesThe stock price didn't jump after Accent Microcell Limited ( NSE:ACCENTMIC ) posted decent earnings last week. We did...Reported Earnings • May 13Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025)Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025).お知らせ • May 08Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026分析記事 • Sep 06Accent Microcell's (NSE:ACCENTMIC) Solid Earnings May Rest On Weak FoundationsAccent Microcell Limited's ( NSE:ACCENTMIC ) robust recent earnings didn't do much to move the stock. We think this is...分析記事 • Oct 25Investors Shouldn't Be Too Comfortable With Accent Microcell's (NSE:ACCENTMIC) EarningsLast week's profit announcement from Accent Microcell Limited ( NSE:ACCENTMIC ) was underwhelming for investors...Reported Earnings • Oct 20First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024)First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses.すべての更新を表示Recent updates分析記事 • May 20Accent Microcell's (NSE:ACCENTMIC) Profits Appear To Have Quality IssuesThe stock price didn't jump after Accent Microcell Limited ( NSE:ACCENTMIC ) posted decent earnings last week. We did...分析記事 • May 19With EPS Growth And More, Accent Microcell (NSE:ACCENTMIC) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • May 13Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025)Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025).お知らせ • May 08Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026New Risk • May 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹8.95b market cap, or US$94.4m).Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹409, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 121% over the past year.New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₹7.22b market cap, or US$80.3m).Board Change • Nov 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Sep 06Accent Microcell's (NSE:ACCENTMIC) Solid Earnings May Rest On Weak FoundationsAccent Microcell Limited's ( NSE:ACCENTMIC ) robust recent earnings didn't do much to move the stock. We think this is...お知らせ • Aug 23Accent Microcell Limited announces Annual dividend, payable on October 25, 2025Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025.お知らせ • Aug 22Accent Microcell Limited, Annual General Meeting, Sep 25, 2025Accent Microcell Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.New Risk • Jul 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹5.93b market cap, or US$67.7m).Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹316, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past year.分析記事 • Jul 19Market Might Still Lack Some Conviction On Accent Microcell Limited (NSE:ACCENTMIC) Even After 25% Share Price BoostDespite an already strong run, Accent Microcell Limited ( NSE:ACCENTMIC ) shares have been powering on, with a gain of...Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹266, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past year.New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹4.84b market cap, or US$56.4m).Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹239, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 23% over the past year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.20b market cap, or US$72.9m).分析記事 • Oct 25Investors Shouldn't Be Too Comfortable With Accent Microcell's (NSE:ACCENTMIC) EarningsLast week's profit announcement from Accent Microcell Limited ( NSE:ACCENTMIC ) was underwhelming for investors...Reported Earnings • Oct 20First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024)First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses.お知らせ • Sep 09Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024.お知らせ • Aug 05Accent Microcell Limited, Annual General Meeting, Sep 09, 2024Accent Microcell Limited, Annual General Meeting, Sep 09, 2024, at 11:30 Indian Standard Time.New Risk • May 19New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risk Market cap is less than US$100m (₹6.90b market cap, or US$82.9m).Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.67 (vs ₹10.06 in FY 2023)Full year 2024 results: EPS: ₹18.67 (up from ₹10.06 in FY 2023). Revenue: ₹2.49b (up 22% from FY 2023). Net income: ₹301.7m (up 132% from FY 2023). Profit margin: 12% (up from 6.4% in FY 2023). The increase in margin was driven by higher revenue.お知らせ • May 18Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹305, the stock trades at a trailing P/E ratio of 49.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹269, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.Recent Insider Transactions • Mar 19CFO, MD & Director recently bought ₹21m worth of stockOn the 14th of March, Ghanshyam Patel bought around 91k shares on-market at roughly ₹231 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹36m. Ghanshyam has been a buyer over the last 12 months, purchasing a net total of ₹57m worth in shares.Recent Insider Transactions • Jan 20CFO, MD & Director recently bought ₹36m worth of stockOn the 16th of January, Ghanshyam Patel bought around 120k shares on-market at roughly ₹301 per share. This transaction increased Ghanshyam's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ghanshyam's only on-market trade for the last 12 months.Board Change • Dec 15Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Accent Microcell の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NSEI:ACCENTMIC 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Mar 263,490439182031 Dec 253,136393187030 Sep 252,782347188030 Jun 252,715339181031 Mar 252,649331174031 Dec 242,625328167030 Sep 242,625325137030 Jun 242,499313130031 Mar 242,456302144031 Mar 231,973122100031 Mar 221,6575977031 Mar 211,3344870031 Mar 201,31542100031 Mar 191,1403685031 Mar 1895318400質の高い収益: ACCENTMIC 非現金収入 のレベルが高いです。利益率の向上: ACCENTMICの現在の純利益率 (12.6%)は、昨年(12.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ACCENTMICの収益は過去 5 年間で年間29%増加しました。成長の加速: ACCENTMICの過去 1 年間の収益成長率 ( 32.7% ) は、5 年間の平均 ( 年間29%を上回っています。収益対業界: ACCENTMICの過去 1 年間の収益成長率 ( 32.7% ) はPharmaceuticals業界15.8%を上回りました。株主資本利益率高いROE: ACCENTMICの 自己資本利益率 ( 15.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/24 23:05終値2026/06/24 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Accent Microcell Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • May 20Accent Microcell's (NSE:ACCENTMIC) Profits Appear To Have Quality IssuesThe stock price didn't jump after Accent Microcell Limited ( NSE:ACCENTMIC ) posted decent earnings last week. We did...
Reported Earnings • May 13Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025)Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025).
お知らせ • May 08Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026
分析記事 • Sep 06Accent Microcell's (NSE:ACCENTMIC) Solid Earnings May Rest On Weak FoundationsAccent Microcell Limited's ( NSE:ACCENTMIC ) robust recent earnings didn't do much to move the stock. We think this is...
分析記事 • Oct 25Investors Shouldn't Be Too Comfortable With Accent Microcell's (NSE:ACCENTMIC) EarningsLast week's profit announcement from Accent Microcell Limited ( NSE:ACCENTMIC ) was underwhelming for investors...
Reported Earnings • Oct 20First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024)First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses.
分析記事 • May 20Accent Microcell's (NSE:ACCENTMIC) Profits Appear To Have Quality IssuesThe stock price didn't jump after Accent Microcell Limited ( NSE:ACCENTMIC ) posted decent earnings last week. We did...
分析記事 • May 19With EPS Growth And More, Accent Microcell (NSE:ACCENTMIC) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • May 13Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025)Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025).
お知らせ • May 08Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026
New Risk • May 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹8.95b market cap, or US$94.4m).
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹409, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 121% over the past year.
New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₹7.22b market cap, or US$80.3m).
Board Change • Nov 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 06Accent Microcell's (NSE:ACCENTMIC) Solid Earnings May Rest On Weak FoundationsAccent Microcell Limited's ( NSE:ACCENTMIC ) robust recent earnings didn't do much to move the stock. We think this is...
お知らせ • Aug 23Accent Microcell Limited announces Annual dividend, payable on October 25, 2025Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025.
お知らせ • Aug 22Accent Microcell Limited, Annual General Meeting, Sep 25, 2025Accent Microcell Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.
New Risk • Jul 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹5.93b market cap, or US$67.7m).
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹316, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past year.
分析記事 • Jul 19Market Might Still Lack Some Conviction On Accent Microcell Limited (NSE:ACCENTMIC) Even After 25% Share Price BoostDespite an already strong run, Accent Microcell Limited ( NSE:ACCENTMIC ) shares have been powering on, with a gain of...
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹266, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past year.
New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹4.84b market cap, or US$56.4m).
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹239, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 23% over the past year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.20b market cap, or US$72.9m).
分析記事 • Oct 25Investors Shouldn't Be Too Comfortable With Accent Microcell's (NSE:ACCENTMIC) EarningsLast week's profit announcement from Accent Microcell Limited ( NSE:ACCENTMIC ) was underwhelming for investors...
Reported Earnings • Oct 20First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024)First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses.
お知らせ • Sep 09Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024.
お知らせ • Aug 05Accent Microcell Limited, Annual General Meeting, Sep 09, 2024Accent Microcell Limited, Annual General Meeting, Sep 09, 2024, at 11:30 Indian Standard Time.
New Risk • May 19New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risk Market cap is less than US$100m (₹6.90b market cap, or US$82.9m).
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.67 (vs ₹10.06 in FY 2023)Full year 2024 results: EPS: ₹18.67 (up from ₹10.06 in FY 2023). Revenue: ₹2.49b (up 22% from FY 2023). Net income: ₹301.7m (up 132% from FY 2023). Profit margin: 12% (up from 6.4% in FY 2023). The increase in margin was driven by higher revenue.
お知らせ • May 18Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹305, the stock trades at a trailing P/E ratio of 49.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹269, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.
Recent Insider Transactions • Mar 19CFO, MD & Director recently bought ₹21m worth of stockOn the 14th of March, Ghanshyam Patel bought around 91k shares on-market at roughly ₹231 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹36m. Ghanshyam has been a buyer over the last 12 months, purchasing a net total of ₹57m worth in shares.
Recent Insider Transactions • Jan 20CFO, MD & Director recently bought ₹36m worth of stockOn the 16th of January, Ghanshyam Patel bought around 120k shares on-market at roughly ₹301 per share. This transaction increased Ghanshyam's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ghanshyam's only on-market trade for the last 12 months.
Board Change • Dec 15Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.